VCN-01 is under clinical development by Theriva Biologics and currently in Phase I for High-Grade Glioma. According to GlobalData, Phase I drugs for High-Grade Glioma does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the VCN-01 LoA Report. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
VCN-01 overview
VCN-01 is under development for the treatment of advanced solid tumors including pancreatic ductal adenocarcinoma and serous epithelial ovarian cancer, recurrent metastatic squamous cell carcinoma of the head and neck, high-grade glioma or brain metastases, pancreatic adenocarcinoma, retinoblastoma. It is administered by intravenous, intravitreal and intratumoral route. It is a tumor-selective replication-competent adenovirus expressing PH20 hyaluronidase. The drug candidate is a genetically engineered adenovirus that is developed based on hyaluronidase technology. It was also under development for the treatment of osteosarcoma, metastatic colorectal cancer and glioblastoma multiforme.
Theriva Biologics overview
Theriva Biologics (Theriva), formerly Synthetic Biologics Inc, is a clinical-stage company. It develops novel therapeutics to treat gut microbiome. The company’s pipeline products include SYN-004 and SYN-010. Its SYN-010 is a proprietary, modified-release formulation that is intended to treat irritable bowel syndrome with constipation. Theriva’s SYN-004 is an oral prophylactic therapy for the prevention of clostridium difficile infection, pathogenic overgrowth and the emergence of antimicrobial resistance. It develops preclinical monoclonal antibody therapies for the treatment of pertussis, and novel discovery-stage biotherapeutics for the treatment of phenylketonuria. The company undertakes various research activities to develop therapeutics. It collaborates with various academic and pharmaceutical companies to develop product candidates. Theriva is headquartered in Rockville, Maryland, the US.
For a complete picture of VCN-01’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
